However, the apparent discrepancy seen through the absence of change in SLC9A1 expression levels throughout the stages of colon cancer, as well as its downregulation in the metastatic group of patients, might suggest that protein activity rather than transcript expression is the most relevant for conferring aggressiveness to colon tumors. The gene discussed is SLC9A1; the disease is malignant colon neoplasm.